Seattle Genetics Company Co- founder, Dr Clay Siegall’s Contributions to Cancer Therapies

Posted on April 4, 2017

Clay Siegall is the President, Chief Executive Officer as well as Chairman of the Board of Seattle Genetic Company, a firm he co-established in 1998. He is a trained scientist who targets cancer therapies, and Seattle Genetic is the perfect place for his work. In his 40s, Clay believes that he still does not know much even though he is the Co-founder of Seattle Genetic Company. Because of this, he is interested in learning as much as he can as well as socializing with other individuals who know much and have expertise in other areas.


Siegall has a passion for helping cancer patients that was born at the age of 19 years when his father was diagnosed with cancer, and he watched him die of it. From what Clay’s father had gone through, Clay sought to improve equipment used by oncologists. This led him pursuing a doctorate in genetics at George Washington University and later worked at the National Cancer Institute of Health from 1988 to 1991. From 1991 to 1997, Clay worked for Bristol-Myers Squibb Pharmaceutical Research Institute where he obtained the basics of operating his own firm.


Seattle Genetics Company developed antibody- drug conjugates and obtained the 2011 FDA approval of its first ADC technology that has generated millions of dollars to date. Dr. Siegall has been at the forefront guiding Seattle Genetics in capital-raising activities, enabling the company to gain more billions through public and private financings.


Dr. Clay has been a recipient of a number of awards. In 2013, he was named Alumnus of the Year for Computer Math and Natural Sciences by the University of Maryland where he studied his B.S. in Zoology. He is a Writer of more than 70 publications and holds its patents. His aim is to improve the cancer treatment methods and make them more effective.


Dr. Siegall states that ADC collaborations have reached technology that allows new ideas and approaches to help patients. He also serves as a board member at Ultragenyx, a pharmaceutical firm that develops novel products for rare and ultra-rare diseases. He is a Director of Alder and Mirna Biopharmaceuticals.

Categories: Drug Development

Comments are closed